Radiprodil - Algernon Pharmaceuticals
Alternative Names: NP 121; RGH-896; UCB-3491Latest Information Update: 28 Aug 2023
Price :
$50 *
At a glance
- Originator Gedeon Richter
- Developer Algernon Pharmaceuticals; Forest Laboratories; Gedeon Richter; PRA Health Sciences; UCB
- Class Antiepileptic drugs; Behavioural disorder therapies; Non-opioid analgesics; Small molecules
- Mechanism of Action NMDA receptor antagonists; NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
- Discontinued Epilepsy; Infantile spasms; Neuropathic pain; Pain; Parkinson's disease
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Canada (PO)
- 03 Jul 2019 Preclinical trials in Idiopathic pulmonary fibrosis in Canada before July 2019 (PO)
- 07 Mar 2019 Discontinued - Phase-I for Epilepsy in Belgium (PO) before March 2019 (UCB Biopharma pipeline, March 2019)